Investigational drug · Phase 2
ONO-2020
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Agitation Associated With Alzheimer's Disease Dementia, Alzheimer Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "ONO-2020"
First trial start
2025
Apr 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ONO-2020", any sponsor or status.
Conditions studied
As listed on its trial records.
- Agitation Associated With Alzheimer's Disease Dementia
- Alzheimer Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ONO-2020" as an intervention, largest first.
- A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseasePivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT06881836 · 260 participants · Start Apr 24, 2025 · Primary completion Jul 31, 2026
Drug: ONO-2020; Placebo · For: Alzheimer Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Sun City, Arizona · 80 sites in all
- A Phase 1 Study of ONO-2020 in Healthy ParticipantsPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT05507515 · 132 participants · Start Jul 29, 2022 · Primary completion Dec 24, 2023
Drug: ONO-2020; Placebo · For: Healthy Volunteers
Sites: Cypress, California
- A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease DementiaRecruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT06803823 · 90 participants (planned) · Start May 1, 2025 · Primary completion Dec 31, 2026
Drug: ONO-2020; Placebo · For: Agitation Associated With Alzheimer's Disease Dementia
Sites: Aichi, Japan; Akita, Japan; Aomori, Japan · 39 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Agitation Associated With Alzheimer's Disease Dementia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.